Powered by Linlax Infotech Pvt Ltd -
  • +91 422 433 22 47 , 48
  • Indian Products Online Store - United States of America [ USA ]      Free Express Shipping on Order above 50 USD
Bal Pharma [ Bal Vedica ]

Welcome to Bal Pharma [ Bal Vedica ] Brand Products Online Store United States of America . Find the Complete List of Bal Pharma [ Bal Vedica ] Products Online for your selection and order.

Bal Pharma Anarsha Capsule
Bal Pharma Ayurfine Forte Capsule
Bal Pharma Ayursulin in PCOs Capsule
Bal Pharma Lipived Capsule
Bal Pharma Prolife Capsule
Bal Pharma Stonex Capsule
Bal Pharma Suswas Capsule
Bal Pharma Ashwamed Capsule
Bal Pharma Ayursulin Capsule
Bal Pharma Immuwin Capsule
Bal Pharma Menoleap Capsule
Bal Pharma Prostowin Capsule
Bal Pharma Sujirna Capsule
Bal Pharma Menoleap Syrup
Bal Pharma Balpro Syrup

About Bal Pharma [ Bal Vedica ]

Bal Pharma is a fully integrated and leading Indian Pharmaceutical Company specializing in Prescription drugs, Generic, OTC products, Intravenous Infusion and Bulk Actives with almost 19 years of experience behind it. 

Bal Pharma’s API’s and Formulations are produced at world class manufacturing facilities. API’s are exported to Europe, Latin America, Africa, Middle East and Asian markets. Formulation products are exported to Semi-Regulated and Non Regulated markets and s strong contender for Tender business in various markets especially Asian markets.

With the new facility being set up in Uttaranchal, as per ICH and PIC guidelines to meet the requirements of USFDA and various European MOH, the company plans to enter in to Regulated Markets by 2010 and already in talks for Contract Manufacturing for clients in Regulated Markets. Successful Operations in Domestic and International markets, backed by its strength in Research and strong Infrastructure frame work have accelerated Bal Pharma’s growth from oblivience to reach a turn over of USD 25 million today. Buoyed by the past, the group has put in motion a fast track growth target and has set its sigh on sales in excess of USD 150 million by 2015.